LogoBiotechNW
The life science and biotech PR distribution service

SomantiX, PharmBioTec and Pharmacelsus Receive €1.5M EUROSTARS Grant for the Small Molecule Preclinical Development Program

EU logo SomantiX logo

 

Utrecht, The Netherlands,  June 30, 2016 / B3C newswire / -- The EUROSTARS grant of EUR 1.5 million is awarded to a multidisciplinary consortium including SomantiX BV, PharmBioTec GmbH and Pharmacelsus GmbH. EUROSTARS is a joint program between EUREKA and the European Commission, co-funded from the national budgets of 36 EUROSTARS Participating States and Partner Countries and by the European Union through Horizon 2020. The subsidy is for a three year period and will allow preclinical development of small molecule inhibitors for anti-vascular and tumor cell invasive therapy in liver cancer.

Ruben Postel, Project Manager and CSO of SomantiX, "We are delighted with the recognition and support for our anti-invasive small molecule program by the EUROSTARS. This strong and synergistic consortium will enable SomantiX to progress preclinical development of our innovative small molecule drugs against our validated cancer target.”


About SomantiX

SomantiX is a Dutch biotech company founded in 2008 by Aglaia Oncology Seed Fund. SomantiX focuses on the development of innovative therapeutics of solid cancers through direct targeting tumor blood vessels. The SomantiX R&D programs focus on target discovery, validation and drug development.

About PharmBioTec
PharmBioTec GmbH is a non-profit Research Organization offering high quality services in Biotechnological/Biopharmaceutical R&D. In 2010 three professors of Saarland University (Prof. Hartmann, Prof. Müller and Prof. Lehr) have combined their extensive knowledge experience in design, synthesis, biological evaluation, formulation and analysis of new drugs to form a young and flexible organization that facilitates free flowing innovation transfer between research and industry. PharmBioTec is a 100% subsidiary of Saarland University.

About Pharmacelsus 
The Pharmacelsus GmbH is a GLP certified Contract Research Organisation (CRO) providing preclinical services. The Pharmacelsus portfolio covers the complete drug discovery and development testing program for small molecules in silico, in vitro, in vivo, ex vivo as well as G(C)LP and non-GLP bioanalysis. Our assays meet national and international regulatory demands.


Contact
Ruben Postel, PhD
CSO SomantiX BV
+31(0)30-7600976
This email address is being protected from spambots. You need JavaScript enabled to view it.

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
Ok